Addex Therapeutics Ltd ADR ADXN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.06
- Day Range
- $3.19–3.65
- 52-Week Range
- $0.00–10.43
- Bid/Ask
- $3.20 / $3.35
- Shares Outstanding
- 1.75M
- Market Cap
- $5.96M
- Volume/Avg
- 18,464 / 570,665
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 79.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
Valuation
Metric | ADXN |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.38 |
Price/Sales | 79.77 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ADXN |
|---|---|
Quick Ratio | 0.59 |
Current Ratio | 0.76 |
Interest Coverage | −2,159.87 |
Quick Ratio
ADXN
Profitability
Metric | ADXN |
|---|---|
Return on Assets (Normalized) | −112.74% |
Return on Equity (Normalized) | −148.35% |
Return on Invested Capital (Normalized) | −146.45% |
Return on Assets
ADXN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|wpJjxD | LOCK|#x#@$ | $132B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|&^%h>? | LOCK|&<!R | $96B | |||
| Moderna Inc MRNA | LOCK|^GgV@SD | LOCK|xw | $81B | |||
| argenx SE ADR ARGX | LOCK|W#Tzd@> | LOCK|?&^ | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|%Dx#^> | LOCK|SVh | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|?CT<w!! | LOCK|&D&H | $30B | |||
| Incyte Corp INCY | LOCK|@?xQXJ | LOCK|<Nh | $24B | |||
| BioNTech SE ADR BNTX | LOCK|<#GZN@ | LOCK|fn | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|pcLmJwr | LOCK|wR^j | $20B | |||
| BridgeBio Pharma Inc BBIO | LOCK|k#p%qL | LOCK|nC< | $15B |